You are about to leave this website and will be redirected to our online portal for healthcare professionals. By continuing, you confirm that you are a healthcare professional.
Fibrotic disorders represent an area of significant unmet need and we currently focus our R&D efforts on Idiopathic Pulmonary Fibrosis (IPF) and adjacent indications involving lung fibrosis.
GLPG4716 is a novel, small molecule CHIT1/AMCase dual-inhibitor targeting a key pathway implicated in inflammation and tissue remodeling. Increased chitinase activity has been observed in several inflammatory, fibrotic diseases. We in-licensed GLPG4716 from Molecure (formerly known as OncoArendi) in November 2020 which we are planning to start a Phase 2 study in lung fibrosis.
